- Pharmaceutical Technology, September 2023
- Volume 47
- Issue 9
- Pages: 26
Size Exclusion Chromatography Columns
Waters Corporation’s XBridge Premier GTx BEH size exclusion chromatography (SEC) columns are designed to improve analysis while lowering the cost of gene therapies.
Waters Corporation’s XBridge Premier GTx BEH size exclusion chromatography (SEC) columns are designed to improve analysis while lowering the cost of gene therapies, specifically for adeno-associated viral (AAV) vectors. SEC is a technique used for aggregate and fragment analysis in the research, development, and manufacturing of biotherapeutic proteins, such as insulin and monoclonal antibodies.
The columns aim to reduce the cost of gene therapies by using three to 10x less sample, generating faster results and offering more drug substance information. Additionally, a new multi-attribute quantification method is intended to double analytical speed, quadruple sensitivity, and increases resolution of target analytes by up to 50%.
The Xbridge columns are designed to take robust physicochemical characterization and quantitative measurements. Aiming to double the speed of measuring the potency and safety of AAVs, the SEC columns are intended for process development, formulation studies, regulatory filing support, ongoing process monitoring, and quality control.
Articles in this issue
over 2 years ago
In Equal Measures: The Importance of Excipient Qualityover 2 years ago
Harnessing the Power of Oncolytic Virusesover 2 years ago
Formulating with Coprocessed Excipients: Current Trendsover 2 years ago
Improving Manufacturing Flexibility with Modulesover 2 years ago
Outsourcing Formulation Services for Biologicsover 2 years ago
Accelerating Clinical Trials in the EUover 2 years ago
Booster Shot for PharmaNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

